GokalR.Taking peritoneal dialysis beyond the year 2000.Perit Dial Int1999; 19(Suppl 3): S35–42.
2.
DaviesS.J., BryanJ., PhillipsL., RussellG.I.Longitudinal changes in peritoneal kinetics: The effects of peritoneal dialysis and peritonitis.Nephrol Dial Transplant1996; 11: 498–506.
3.
SelgasR., Fernandez–ReyesM-J, BosqueE., BajoM-A, BorregoF., JimenezC.Functional longevity of the human peritoneum: How long is continuous peritoneal dialysis possible? Results of a prospective median long-term study.Am J Kidney Dis1994; 23: 64–73.
4.
HeimbürgerO., WaniewskiJ., WerynskiA., TranæusA., LindholmB.Peritoneal transport in CAPD patients with permanent loss of ultrafiltration capacity.Kidney Int1990; 38: 495–506.
5.
Di PaoloN., SacchiG.Atlas of peritoneal histology.Perit Dial Int2000; 20(Suppl 3): S5–96.
6.
WilliamsJ.D., CraigK.J., TopleyN., Von RuhlandC., FallonM., NewmanG.R.Peritoneal Biopsy Study Group. Morphologic changes in the peritoneal membrane of patients with renal disease.J Am Soc Nephrol2002; 13: 470–9.
7.
HondaK., NittaK., HoritaS., YumuraW., NiheiH.Morphological changes in the peritoneal vasculature of patients on CAPD with ultrafiltration failure.Nephron1996; 72: 171–6.
8.
RubinJ., HerreraG.A., CollinsD.An autopsy study of the peritoneal cavity from patients on continuous ambulatory peritoneal dialysis.Am J Kidney Dis1991; 18: 97–102.
9.
FracassoA., BaggioB., OssiE., Del PreteD., BonfanteL., BazzatoG.Glycosaminoglycans prevent the functional and morphological peritoneal derangement in an experimental model of peritoneal fibrosis.Am J Kidney Dis1999; 33: 105–10.
10.
HondaK., NittaK., HoritaS., YumuraW., NiheiH., NagaiR.Accumulation of advanced glycation end products in the peritoneal vasculature of continuous ambulatory peritoneal dialysis patients with low ultra-filtration.Nephrol Dial Transplant1999; 14: 1541–9.
YangJ., LiuY.Dissection of key events in tubular epithelial to myofibroblast transition and its implications in renal interstitial fibrosis.Am J Pathol2001; 159: 1465–75.
15.
StrutzF., MullerG.A.Transdifferentiation comes of age.Nephrol Dial Transplant2000; 15: 1729–31.
16.
WolfG., NeilsonE.G.Angiotensin II as a renal growth factor.J Am Soc Nephrol1993; 3: 1531–40.
17.
MezzanoS.A., Ruiz-OrtegaM., EgidoJ.Angiotensin II and renal fibrosis.Hypertension2001; 38: 635–8.
18.
AndersenS., TarnowL., RossingP., HansenB.V., ParvingH.H.Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy.Kidney Int2000; 57: 601–6.
19.
BorderW.A., NobleN.A.TGF β in kidney fibrosis: A target for gene therapy.Kidney Int1997; 51: 1388–96.
20.
PetersH., BorderW.A., NobleN.A.Targeting TGF β overexpression in renal disease: Maximizing the antifibrotic action of angiotensin II blockade.Kidney Int1998; 54: 1570–80.
21.
Ruiz-OrtegaM., RuperezM., LorenzoO., EstebanV., BloncoJ., MezzanoS.ANG II also regulates the synthesis of proinflammatory cytokines and chemokines in the kidney.Kidney Int Suppl2002; 82: S12–22.
22.
LodsN., FerrariP., FreyF.J., KappelerA., BerthierC., VogtB.Angiotensin-converting enzyme inhibition but not angiotensin II receptor blockade regulates matrix metalloproteinase activity in patients with glomerulonephritis.J Am Soc Nephrol2003; 14: 2861–72.
23.
LiuB.C., SunJ., ChenQ., MaK.L., RuanX.Z., PhillipsA.O.Role of connective tissue growth factor in mediating hypertrophy of human proximal tubular cells induced by angiotensin II.Am J Nephrol2003; 23: 429–37.
24.
MaL.J., YangH., GaspertA., CarlessoG., BartyM.M., DavidsonJ.M.Transforming growth factor-beta-dependent and -independent pathways of induction of tubulointerstitial fibrosis in beta6(–/–) mice.Am J Pathol2003; 163: 1261–73.
25.
ThomasD.W., HoffmanM.D.Identification of macrophage receptor for angiotensin: A potential role in antigen uptake for T lymphocyte responses?J Immunol1984; 132: 2807–12.
26.
LagnaG., HataA., MassaguéJ.Partnership between DPC4 and SMAD protein in TGF-beta signalling pathways.Nature1996; 383: 832–6.
27.
FujiyamaS., MatsubaraH., NozawaY., MaruyamaK., MoriY., TsutsumiY.Angiotensin AT(1) and AT(2) receptors differentially regulate angiopoietin-2 and vascular endothelial growth factor expression and angiogenesis by modulating heparin binding-epidermal growth factor (EGF)-mediated EGF receptor trans-activation.Circ Res2001; 88: 22–9.
28.
RizkallaB., ForbesJ.M., CooperM.E., CaoZ.Increased renal vascular endothelial growth factor and angiopoietins by angiotensin II infusion is mediated by both AT1 and AT2 receptors.J Am Soc Nephrol2003; 14: 3061–71.
29.
YaoQ., LindholmB., QianJ.Inhibition of the effect of high glucose (HG) on the expression of Smad in human peritoneal mesothelial cells [Abstract].J Am Soc Nephrol2003; 14: 215A.
30.
NohH., KimH.J., YuM.R., HaH., LeeH.B.Renin angiotensin system in human peritoneal mesothelial cells [Abstract].J Am Soc Nephrol2003; 14: 218A.
31.
SawadaT., IshiiY., TojimbaraT., NakajimaI., FuchinoueS., TeraokaS.The ACE inhibitor, quinapril, ameliorates peritoneal fibrosis in an encapsulating peritoneal sclerosis model in mice.Pharmacol Res2002; 46: 505–10.
32.
AbeK., MiyazakiM., YoshioY., FurusuA., HaradaT., SugayaT.Importance of angiotensin II type 1 receptor in bone marrow derived cells in the progression of peritoneal fibrosis [Abstract].J Am Soc Nephrol2003; 14: 36A.
33.
ImaiH., NakamotoH., IshidaY., YamanouchiY., InoueT., OkadaH.Renin-angiotensin system plays an important role in the regulation of water transport in the peritoneum.Adv Perit Dial2001; 17: 20–4.
DumanS., ŞenS., AşçiG., BaşçiA., AkçiçekF.Effect of valsartan versus lisinopril on peritoneal alterations in rats [Abstract].Perit Dial Int2002; 22: 112.
36.
DumanS., ŞenS., DumanC., AşciG., BasciA., AkcicekF.Improvement of peritoneal alterations induced by hypertonic PD solutions by ACE inhibitors and by AR blockers [Abstract].Nephrol Dial Transplant2003; 18(Suppl 4): s474.
37.
AgraharkarM., DuY., Man-WanC., HenryS., KuoY.F., AhujaT.Angiotensin II receptor blockade (ARB) and peritoneal protein loss in peritoneal dialysis patients [Abstract].J Am Soc Nephrol2003; 14: 858A.
38.
AndersenS., TarnowL., RossingP., HansenB.V., ParvingH.H.Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patient with diabetic nephropathy.Kidney Int2000; 57: 601–6.
39.
BauerJ.H., ReamsG.P., HewettJ., KlachkoD., LauA., MessinaC.A randomized, double blind, placebo-controlled trial to evaluate the effect of enalapril in patients with clinical diabetic nephropathy.Am J Kidney Dis1992; 20: 443–57.
40.
RuggenentiP., PernaA., GherardiG., GaspariF., BeniniR., RemuzziG.Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Nephropathy.Lancet1998; 352: 1252–6.
41.
RuggenentiP., PernaA., GherardiG., GariniG., ZoccaliC., SalvadoriM.Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with nonnephrotic proteinuria.Lancet1999; 354: 359–64.
42.
LiP.K., ChowK.M., WongT.Y., LeungC.B., SzetoC.C.Effects of an angiotensin-converting enzyme inhibitor on residual renal function in patients receiving peritoneal dialysis. A randomized, controlled study.Ann Intern Med2003; 139: 105–12.
43.
KikutaT., WatanabeY., KannoY., TomoriK., NakamotoH., OkadaH.Effects of angiotensin II-receptor blocker, valsartan, on residual renal function in patients on CAPD [Abstract].J Am Soc Nephrol2003; 14: 482A.
44.
KagamiS., BorderW.A., MillerD.E., NobleN.A.Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-beta expression in rat glomerular mesangial cells.J Clin Invest1994; 93: 2431–7.
45.
FavaS., AzzopardiJ., EllardS., HattersleyA.T.ACE gene polymorphism as a prognostic indicator in patients with type 2 diabetes and established renal disease.Diabetes Care2001; 24: 2115–20.
46.
AzarS.T., ZallouaP.A., MedlejR., HalabiG.The DD genotype of the ACE gene polymorphism is associated with diabetic nephropathy in the type-1 diabetics.Endocr Res2001; 27: 99–108.
47.
NishinaM.A study on angiotensin-I converting enzyme polymorphism in CAPD patients.Nippon Jinzo Gakkai Shi1996; 38: 595–602.
48.
WangA.Y., ChanJ.C., WangM., PoonE., LuiS.F., LiP.K.Cardiac hypertrophy and remodeling in relation to ACE and angiotensinogen genes genotypes in Chinese dialysis patients.Kidney Int2003; 63: 1899–907.
